^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Thyroid Gland Medullary Carcinoma
    Drug:Cometriq (cabozantinib capsule) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    10/22/2020
    Excerpt:
    COMETRIQ is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    03/21/2014
    Excerpt:
    COMETRIQ is indicated for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Future Oncol
    Title:

    Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer

    Published date:
    07/31/2013
    Excerpt:
    A Phase III clinical trial (EXAM study) of XL184 versus placebo in advanced and progressive medullary thyroid cancer showed a 28 versus 0% overall response rate and a progression-free survival of 11.2 versus 4.0 months (hazard ratio: 0.28; 95% CI: 0.19–0.40; p < 0.0001) in patients treated with cabozantinib and placebo, respectively.
    Trial ID:
    NCT00704730